These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis. Li H; Duan Y; Chen B; Zhao Y; Su W; Wang S; Wu J; Lu L Medicine (Baltimore); 2020 Jan; 99(5):e18341. PubMed ID: 32000355 [TBL] [Abstract][Full Text] [Related]
23. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. Coats AJS; Tolppanen H Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of Intravenous Iron in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Systematic Review and Meta-Analysis of Randomized Control Trials. Sephien A; Dayto DC; Reljic T; Prida X; Joly JM; Tavares M; Katz JN; Kumar A Am J Cardiovasc Drugs; 2024 Mar; 24(2):285-302. PubMed ID: 38519808 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness of self-management programmes for heart failure with reduced ejection fraction: a systematic review protocol. Iyngkaran P; Buhler M; de Courten M; Hanna F BMJ Open; 2024 Jun; 14(6):e079830. PubMed ID: 38839380 [TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review. Schmidt R; Rodrigues CG; Schmidt KH; Irigoyen MCC ESC Heart Fail; 2020 Feb; 7(1):3-14. PubMed ID: 31965746 [TBL] [Abstract][Full Text] [Related]
27. Sex differences in the efficacy of antihypertensive treatment in preventing cardiovascular outcomes and reducing blood pressure: protocol for a systematic review and meta-analysis. Gasbarrino K; Labos C; Mastropietro V; Hales L; Khan N; Rabi D; Daskalopoulou SS BMJ Open; 2020 Mar; 10(3):e036128. PubMed ID: 32169929 [TBL] [Abstract][Full Text] [Related]
28. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis. Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696 [TBL] [Abstract][Full Text] [Related]
30. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854 [TBL] [Abstract][Full Text] [Related]
33. The prognosis of mid-range ejection fraction heart failure: a systematic review and meta-analysis. Altaie S; Khalife W ESC Heart Fail; 2018 Dec; 5(6):1008-1016. PubMed ID: 30211480 [TBL] [Abstract][Full Text] [Related]
34. The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. Papademetriou V; Toumpourleka M; Imprialos KP; Alataki S; Manafis A; Stavropoulos K Curr Pharm Des; 2018; 24(46):5517-5524. PubMed ID: 30806305 [TBL] [Abstract][Full Text] [Related]
35. Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis. Thevathasan T; Colbatzky T; Schmelzle M; Pratschke J; Krenzien F BMJ Open; 2021 Aug; 11(8):e045733. PubMed ID: 34376442 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of bilevel positive airway pressure and continuous positive airway pressure therapy in patients with obesity hypoventilation syndrome: protocol for systematic review and meta-analysis. Guan L; Wu W; Huo Y; Li X; Guo B; Yang Y; Xu J; Jiang F; Zhou L; Chen R BMJ Open; 2018 May; 8(5):e020832. PubMed ID: 29724743 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of different modes of exercise-based cardiac rehabilitation delivery for patients with heart failure: a protocol for a systematic review and network meta-analysis. Jiang L; Wan R; Li B; Huang X; Xu Y; Wu K; Xu J; Lu Y BMJ Open; 2022 Aug; 12(8):e062152. PubMed ID: 35926991 [TBL] [Abstract][Full Text] [Related]
38. How does HbA1c predict mortality and readmission in patients with heart failure? A protocol for systematic review and meta-analysis. Xu JP; Zeng RX; Mai XY; Pan WJ; Zhang YZ; Zhang MZ Syst Rev; 2023 Mar; 12(1):35. PubMed ID: 36899409 [TBL] [Abstract][Full Text] [Related]
39. Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure. Silva-Cardoso J; Brás D; Canário-Almeida F; Andrade A; Oliveira L; Pádua F; Fonseca C; Bragança N; Carvalho S; Soares R; Santos JF Rev Port Cardiol (Engl Ed); 2019 Mar; 38(3):175-185. PubMed ID: 31029493 [TBL] [Abstract][Full Text] [Related]
40. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Pannaux M; Swedberg K Eur J Heart Fail; 2018 Sep; 20(9):1315-1322. PubMed ID: 29806165 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]